Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101, Pembrolizumab and Gemcitabine in Metastatic Pancreatic Cancer
NCT06498518Phase 2Withdrawn
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM-101 in pancreatic adenocarcinoma (PDAC). Planned start Jun 2024; status: withdrawn.
02
Drugs
IMM-101
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06498518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498518.